Get the Stockscreener App
125.46
1.77%
2.18
After Hours:
125.60
0.14
+0.11%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $125.46, with a volume of 4.76M.
It is up +1.77% in the last 24 hours and down -2.61% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$123.28
Open:
$123.47
24h Volume:
4.76M
Relative Volume:
0.77
Market Cap:
$218.16B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.74
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
+0.30%
1M Performance:
-2.61%
6M Performance:
-8.05%
1Y Performance:
+10.19%
1-Day Range:
$122.91
$125.58
1-Week Range:
$120.70
$125.58
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories (ABT) Expands Board of Directors with New Ap - GuruFocus
Abbott Laboratories Expands Board with New Appointment - TipRanks
Abbott Laboratories (ABT) Stock: Dividend Boost and Major Acquisition Drive 2026 Outlook - CoinCentral
Abbott Laboratories (ABT) Boosts Quarterly Dividend by 6.8% - GuruFocus
Abbott Laboratories Declares 408th Consecutive Quarterly Cash Common Dividend, Payable on February 13, 2026 - marketscreener.com
Abbott (ABT) Raises Quarterly Dividend by 6.8% - GuruFocus
Syringe Pumps Industry Intelligence Report 2025-2032: Focus on Product Types, Material Types, Mode of Operation, End Users, Regions, Groups, Countries - GlobeNewswire Inc.
Abbott Raises Quarterly Dividend to $0.63 a Share, Payable Feb. 13 to Holders of Record as of Jan. 15 - marketscreener.com
Abbott increases quarterly dividend by 6.8% for 54th consecutive year - Investing.com
Abbott (NYSE: ABT) boosts dividend to $0.63, marking 408th straight quarterly payout - Stock Titan
Abbott Laboratories price tries to recoup some lossesForecast today12-12-2025 - Economies.com
Assessing Abbott (ABT) Valuation After New Lingo CGM Expansion and Protein-Glucose Data Release - simplywall.st
Technology that connects you to what matters most: Your health - Abbott
Abbott Presses Congress for Shield Over Preemie Baby Formula Litigation That Could Cost It Billions - Claims Journal
Abbott Announces Its New Specialty and Metabolic Powder Nutritional Manufacturing Facility Will Be in Bowling Green, Ohio - Abbott
The Abbott World Marathon Majors - Abbott
Our People And Culture - Abbott
Responsibility - Abbott
Sustainability - Abbott
Abbott Fund - Abbott
Diagnostics Testing Products and Solutions | Abbott U.S. - Abbott
Pain and Movement - Abbott
Our Products | Full Products and Solutions List | Abbott U.S. - Abbott
Medicines | Medicines, Biosimilars and Therapies in Emerging Markets | Abbott U.S. - Abbott
Benefits - Abbott
Early Career Opportunities for Students | Internships and Co-Ops | Abbott U.S. - Abbott
Products and Solutions - Abbott
About Abbott | Company Overview, Mission and Values - Abbott
Investors - Abbott
Careers | Find Abbott Jobs and Internships - Abbott
Leadership - Abbott
Cardiovascular Products and Solutions | Medical Devices for the Heart | Abbott U.S. - Abbott
Newsroom | Top Stories | Abbott U.S. - Abbott
PREEMPTION—MEDICAL DEVICES—D. Nev.: Products liability action against Abbott Labs over its Trifecta heart valve preempted by federal law - VitalLaw.com
Abbott to Acquire Exact Sciences for $21 Billion - MSN
Abbott Laboratories (ABT) Seeks Legal Shield Amid Infant Formula Lawsuits - GuruFocus
Abbott's Billion-Dollar Threat: Pull the Plug or Get a Bailout? - TradingView
Abbott asks Congress to shield it baby formula lawsuitsreport (ABT:NYSE) - Seeking Alpha
Abbott Appeals To Revive Glucose Monitoring Patent - Law360
Abbott Presses Congress for Legal Shield Over Preemie Baby Formula Lawsuits - Insurance Journal
Abbott Fired a Warning Shot on Baby Formula — Then Launched a Lobbying Blitz - Bloomberg.com
Abbott’s Strategic Shift: A $21 Billion Bet on Cancer Diagnostics - Ad-hoc-news.de
Rep. Richard Dean Dr McCormick Has Bought Up to $390K Worth Of Abbott Laboratories Stock: Here's What You Should Know - Benzinga
Vanguard Group Inc's Strategic Acquisition of Abbott Laboratories Shares - GuruFocus
Investment Management Corp of Ontario Sells 32,347 Shares of Abbott Laboratories $ABT - MarketBeat
Ossiam Has $8.77 Million Position in Abbott Laboratories $ABT - MarketBeat
Institutional shareholders may be less affected by Abbott Laboratories' (NYSE:ABT) pullback last week after a year of 8.3% returns - Yahoo Finance
Daiwa Securities Group Inc. Has $37.79 Million Position in Abbott Laboratories $ABT - MarketBeat
Here's Why Abbott (ABT) Fell More Than Broader Market - Yahoo Finance
Abbott (ABT) Expands Lingo Glucose Monitor to Android Users - GuruFocus
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump - AOL.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):